MicroRNAs (miRNAs) have emerged as critical regulators in cancer progression. miR-613 has been reported as a tumor suppressor gene in many types of human cancers. However, the function of miR-613 in renal cell carcinoma (RCC) remains unclear. In the present study, the authors aimed to detect the expression of miR-613 and its function in RCC cell lines. miR-613 was reported to be significantly downregulated RCC cell lines. Functional analyses demonstrated that overexpression of miR-613 significantly decreased RCC cell proliferation and invasion. Bioinformatics analysis showed that Frizzled7 (FZD7) was a predicted target of miR-613, which was verified by dual-luciferase reporter assay, reverse transcription quantitative-polymerase chain reaction and western blot analysis. Restoration of FZD7 significantly reversed the suppressive effects of miR-613 on RCC cell proliferation and invasion. Taken together, the results of the present study indicated that miR-613 functions as a tumor suppressor that inhibits RCC cell proliferation and invasion by targeting and inhibiting FZD7, providing novel insight into RCC pathogenesis and a potential therapeutic target for RCC.
Introduction
Renal cell carcinoma (RCC) is the most prevalent malignancy of the adult kidney, accounting for ~90% of kidney tumors and 3% of cancers in adults (1, 2) . The morbidity and mortality of RCC have increased steadily in recent years (3) . Despite advances in cancer therapies, RCC is an intractable disease, and most affected patients undergo metastasis development and relapse after treatment (4, 5) . The molecular mechanism of RCC pathogenesis is still elusive, hampering the development of effective therapeutics. Therefore, specifically targeted therapies to improve the survival rate of RCC based on molecular mechanisms are urgently required.
MicroRNAs (miRNAs) are a class of conserved non-coding RNAs of ~22 nucleotides in length that serve an important role in regulating gene expression (6, 7) . miRNAs can directly target the 3'-untranslated region (UTR) of the mRNA to induce mRNA degradation and translation inhibition (6, 7) . A growing body of evidence has indicated that miRNAs are critical regulators of cancer development and progression that regulate cell proliferation, apoptosis, differentiation, migration and invasion by functioning as either oncogenes or tumor suppressors (8) (9) (10) . Increasing evidence has reported that various miRNAs are dysregulated in RCC, contributing to the pathogenesis of RCC and can serve as potential diagnostic and prognostic biomarkers and therapeutic targets of RCC (11) (12) (13) . However, the precise role of miRNAs in RCC remains largely unknown.
Frizzled7 (FZD7) is an important co-receptor in the Wnt signaling pathway (14, 15) . Aberrant expression of FZD7 occurs frequently in numerous cancers and is associated with abnormal activation of the Wnt signaling pathway (16) (17) (18) (19) . FZD7 regulates cancer cell proliferation, invasion and metastasis by promoting the Wnt signaling pathway (20, 21) . Wnt signaling is extensively involved in the progression of RCC (22) . High expression of FZD7 has been reported in RCC tissues and cell lines and contributes to Wntmediated RCC progression (23) . Therapy targeting the FZD7 signaling pathway may have potential therapeutic value in the treatment of RCC.
Two recent studies indicated that miR-613 is a tumorassociated miRNA in various cancer types (24, 25) ; however, the role of miR-613 in RCC remains unknown. The present study intended to investigate the expression and role of miR-613 in RCC. The results demonstrated that miR-613 was frequently decreased in RCC cell lines. Overexpression of miR-613 significantly inhibited RCC cell proliferation and invasion. Bioinformatics analysis and dual-luciferase reporter assay demonstrated that FZD7 was a direct target of miR-613. Further data indicated that FZD7 contributed to miR-613-endowed effects, including cell proliferation and invasion. Taken together, these findings indicated that miR-613 inhibits RCC cell proliferation and invasion by targeting FZD7, suggesting a potential therapeutic candidate for RCC.
Materials and methods
Cell lines. Human RCC cell lines, including ACHN, 786-O, A498 and Caki-2, and a human renal proximal tubule epithelial cell line (HK-2) were purchased from the American Type Culture Collection (Manassas, VA, USA). RCC cells were cultured in Dulbecco's modified Eagle medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 1% penicillin/streptomycin mix (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.). HK-2 cells were cultured with F-12K medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS (Invitrogen; Thermo Fisher Scientific, Inc.) and 1% penicillin/streptomycin mix (Sigma-Aldrich; Merck KGaA). All cells were cultured within a humidified atmosphere containing 5% CO 2 /95% air at 37˚C.
RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis.
Total RNA was extracted from tissues or cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Reverse transcription of mRNA and miRNA were performed by Super M-MLV Reverse Transcriptase (BioTeke Corporation, Beijing, China) or miScript reverse transcription kit (Qiagen GmbH, Hilden, Germany), respectively, according to the manufacturer's instructions. PCR amplification was carried out with an Applied Biosystems AB7500 Real Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) under the following conditions: 94˚C for 10 min; 35 cycles of 94˚C for 20 sec, 55˚C for 30 sec and 72˚C for 30 sec; and 72˚C for 5 min. The reactions were performed using sing Power SYBR-Green PCR Master Mix (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primers used were as follows: miR-613 forward, 3'-CGT TTC TTC CTT GTA AGGA-5' and reverse, 5'-CCC AAG CTT GTT GGA GAA CAG CAG CGA GGAC-3'; U6 forward, 5'-GCT TCG GCA GCA CAT ATA CTA AAAT-3' and reverse, 5'-CGC TTC ACG AAT TTG CGT GTC AT-3'; FZD7, forward: 5'-CCA ACG GCC TGA TGT ACT TT-3' and reverse, 5'-ATG AAG TAG CAG CCC GAC AG-3'; and GAPDH forward, 5'-CCA TGT TCG TCA TGG GTG TG-3' and reverse, 5'-GGT GCT AAG CAG TTG GTG GTG-3'. The data was analyzed by the 2 -ΔΔCq method (26) . The relative expression of FZD7 was obtained by normalization to GAPDH. The relative expression of miR-613 was obtained by normalization to U6.
Cell transfection. The miR-613 mimics and negative control miRNAs (miR-NC) used in the current study were synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). The full-length cDNA of FZD7 without 3'-UTR region was cloned into the pcDNA3.0 vector (Invitrogen; Thermo Fisher Scientific, Inc.) to generate pcDNA3/FZD7 overexpressing vectors. The miRNAs and vectors were transiently transfected into cells using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions.
MTT assay. Cells were plated into 96-well plates at a density of 1x10 4 cells/well and cultured for 24 h. The cells were then transfected with miR-613 mimics or miR-NC for 24, 48 and 72 h. Thereafter, 20 µl 5 mg/ml MTT solution (Sigma-Aldrich; Merck KGaA) was added to each well. Following incubation for another 4 h, the medium was discarded and 150 µl dimethyl sulfoxide (Sigma-Aldrich; Merck KGaA) was added to each well to dissolve the formazan products. The absorbance of the converted dye was detected at a wavelength of 490 nm using a microplate spectrophotometer (Bio-Tek Instruments, Inc., Winooski, VT, USA).
Colony formation assay. Cells were transfected with miR-613 mimics or miR-NC for 48 h, and then the transfected cells were seeded into six-well plates at a density of 100 cells/well and cultured in growth medium containing 0.3% noble agar for 14 days. The colonies were stained with 0.1% crystal violet (Sigma-Aldrich; Merck KGaA) and counted under the microscope (Olympus Corporation, Tokyo, Japan).
Cell invasion assay. The cell invasion assay was performed by Matrigel invasion assay. Briefly, Transwell membrane filter inserts were precoated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). A total of 500 µl serum-free medium containing 1x10 5 cells transfected with miR-613 mimics or miR-NC was placed into the top chamber. Meanwhile, 500 µl growth medium containing 10% FBS was placed into the lower chamber. Cells were cultured at 37˚C for 24 h, noninvasive cells on the top well were gently scraped by a cotton swab. The invaded cells were fixed with methanol and stained with 0.1% crystal violet (Sigma-Aldrich; Merck KGaA). Stained cells were counted under light microscopy (Olympus Corporation).
Western blot analysis. Cells were harvested and lysed in radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Haimen, China). Protein concentration was measured using a bicinchoninic acid assay kit (Beyotime Institute of Biotechnology). A total of 25 µg protein was separated by SDS-PAGE (Sangon Biotech Co., Ltd., Shanghai, China). The separated proteins were electro-transferred to a polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA). The membrane was blocked in 3% nonfat milk and incubated with primary anti-FZD7 (1:250; Abcam, Cambridge, UK; cat. no. ab64636) or anti-GAPDH (1:1,000; Abcam; cat. no. ab9485) antibodies at 4˚C overnight, followed by incubation with horseradish peroxidase-conjugated secondary antibodies (1:2,000; BIOSS, Beijing, China; cat. no. bs-0295G-HRP) for 1 h at 37˚C. The protein bands were developed using an enhanced chemiluminescence western blotting kit (EMD Millipore). Densitometry analysis of the protein blots was conducted using Image-Pro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA) and normalized to GAPDH.
Dual-luciferase reporter assay. The 3'-UTR of FZD7 containing miR-613 binding sites was cloned into the pmirGLO Dual-Luciferase Vector (Promega Corporation, Madison, WI, USA) to generate wild-type (WT) pmirGLO-FZD7. The 3'-UTR of FZD7 containing mutations in the miR-613 recognition sites was synthesized using a Site-Directed Mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA, USA) and cloned into the pmirGLO Dual-Luciferase Vector to generate mutant (MT) pmirGLO-FZD7. The pmirGLO Dual-Luciferase Vectors were cotransfected with miR-613 mimics or miR-NC using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) and incubated for 48 h. Relative luciferase activity was detected using the Dual-Glo Luciferase Assay system (Promega Corporation).
Data analysis. All results were presented as means ± standard deviation and analyzed using SPSS software (version, 11.5; SPSS Inc., Chicago, IL, USA). Differences were assessed for significance by Student's t-test and one-way analysis of variance followed by Bonferroni's post hoc test according to the data characteristics. P<0.05 was considered to indicate a statistically significant difference.
Results

Downregulation of miR-613 occurs frequently in RCC.
To explore the relevance of miR-613 in RCC, the authors examined the expression profile of miR-613 in four RCC cell lines (ACHN, 786-O, A498 and Caki-2) using the human renal proximal tubule epithelial cell line HK-2 as a control. The results demonstrated that the expression of miR-613 was markedly decreased by 80% in ACHN (P<0.05), 77% in 786-O (P<0.05), 61% in A498 (P<0.05) and 56% in Caki-2 (P<0.05) cells as compared with HK-2 cells (Fig. 1) . These results indicated that downregulation of miR-613 is a common event in RCC that may contribute to the pathogenesis of RCC.
Overexpression of miR-613 inhibits RCC cell proliferation. To investigate the possible biological function of miR-613 in RCC cells, the authors transfected ACHN and 786-O cells with miR-613 mimics or negative miRNAs (miR-NC). The transfection efficiency was verified by RT-qPCR analysis, which indicated that the miR-613 expression level was significantly increased by 6.87-fold (P<0.01) in miR-613 mimic-transfected ACHN cells ( Fig. 2A) and increased by 5.96-fold (P<0.01) in miR-613 mimic-transfected 786-O cells (Fig. 2B ) compared with the control. Following this, the effect of miR-613 overexpression on RCC cells was examined by MTT assay. The results identified that overexpression of miR-613 significantly decreased RCC proliferation of ACHN ( Fig. 2C; P<0 .05) and 786-O ( Fig. 2D; P<0 .05) cells. To confirm the inhibitory effect of miR-613 on RCC cell proliferation, the authors further performed a colony formation assay. The results demonstrated that miR-613 overexpression significantly inhibited colony-forming capacity by 40% in ACHN ( Fig. 2E; P<0 .05) and 62.5 in 786-O ( Fig. 2F; P<0 .05) cells. These results indicated that miR-613 suppresses RCC cell proliferation.
Overexpression of miR-613 suppresses RCC cell invasion.
To further investigate the biological role of miR-613 in RCC cells, the authors performed an invasion assay to detect the effect of miR-613 overexpression on RCC cell invasion. The results demonstrated that miR-613 overexpression significantly repressed the invasive ability of ACHN by 55% ( Fig. 3A;  P<0 .05) and 786-O by 61% ( Fig. 3B; P<0 .05) cells. These results suggested that miR-613 inhibits RCC cell invasion.
FZD7 is the direct target of miR-613. To investigate the molecular mechanism by which miR-613 inhibits RCC cell proliferation and invasion, potential target genes of miR-613 were screened by bioinformatics analysis. Interestingly, the authors reported that FZD7, a well-known oncogene in various cancers (18) , was predicted to be a target of miR-613 ( Fig. 4A ). To verify whether FZD7 is the direct target gene of miR-613, a dual-luciferase reporter assay was conducted. Cotransfection of the WT FZD7 3'-UTR construct with miR-613 mimics inhibited luciferase activity by 58% in ACHN ( Fig. 4B; P<0 .05) and 62% in 786-O ( Fig. 4C ; P<0.05) cells. However, overexpression of miR-613 reported no obvious effect on the MT FZD7 3'-UTR construct ( Fig.  4B and C; P>0.05). Furthermore, the effect of mIR-613 on FZD7 expression was detected. The results demonstrated that miR-613 overexpression inhibited FZD7 mRNA expression by 56% in ACHN ( Fig. 5A; P<0 .05) and 53% in 786-O ( Fig. 5B; P<0 .05) cells. Furthermore, miR-613 overexpression remarkably suppressed FZD7 protein expression by 81% in ACHN ( Fig. 5C; P<0 .01) and 89% in 786-O ( Fig. 5D ; P<0.01) cells. Taken together, these results indicated that miR-613 directly targets the 3'-UTR of FZD7 and inhibits FZD expression in RCC cells.
Restoration of FZD7 rescues the tumor suppressive effect of miR-613.
To investigate whether the tumor suppressive effect of miR-613 on RCC cell proliferation and invasion was mediated by FZD7 repression, FZD7 expression in miR-613-overexpressing cells was restored by transfection with pcDNA3 vectors expressing FZD7 without the 3'-UTR region. The results indicated that the reduced expression of FZD7 induced by miR-613 mimics was significantly restored by 92% in ACHN ( Fig. 6A; P<0 .01) and 83% in 786-O ( Fig. 6B; P<0 .01) cells transfected with pcDNA3/FZD7 vector. As expected, the inhibitory effect of miR-613 on RCC cell proliferation was reversed by 90% in ACHN and 87% in 786-O ( Fig. 7A ; P<0.05) cells by FZD7 overexpression. In addition, the inhibitory effect of miR-613 on RCC cell invasion was reversed by 81% in ACHN and 77% in 786-O ( Fig. 7A; P<0 .05) cells by FZD7 overexpression. These results implied that miR-613 inhibits RCC cell proliferation and invasion by targeting FZD7. 
Discussion
A growing body of evidence suggests that miRNAs regulate a variety of genes involved in RCC progression (11) (12) (13) . Therefore, identification of RCC-associated miRNAs as biomarkers for diagnosis, prognosis and therapeutic targets for RCC treatment is of great importance. In the present study, the authors have revealed that miR-613 is frequently downregulated RCC cell lines. Functional analysis demonstrated that miR-613 overexpression repressed RCC cell proliferation and invasion. Moreover, the findings identified and verified FZD7 as the direct target gene of miR-613 in RCC cells. Rescuing FZD7 expression significantly reversed the suppressive effect of miR-613 on RCC proliferation and invasion. Taken together, the results of the current study suggested that miR-613 inhibits RCC cell proliferation and invasion through targeting FZD7. Two recent studies have reported that several miRNAs are abnormally expressed in RCC and involved in RCC pathogenesis. For example, miR-196a and miR-149-5p are significantly downregulated in RCC and associated with proliferation, apoptosis, and migration (27, 28) . Das et al (29) reported that overexpression of miR-214 inhibited RCC proliferation by targeting the insulin-like growth factor-1 receptor. Gao et al (30) reported that miR-155 promotes RCC proliferation and invasion by inhibiting E2F2. In the current study, the authors stated that miR-613 also functioned as an RCC-associated miRNA. However, the precise role of miR-613 in RCC remains unknown. miR-613 was downregulated in RCC cell lines and overexpression of miR-613 inhibited RCC cell proliferation and invasion. These data suggested that miR-613 functions as a tumor suppressor in RCC.
To date, various studies have proposed a tumor-suppressive role of miR-613 in many types of cancers. Decreased expression of miR-613 has been suggested as novel diagnostic and prognostic biomarker for esophageal squamous-cell carcinoma (31) and ovarian cancer (32) . Fu et al (33) reported that miR-613 suppressed ovarian cancer cell proliferation and invasion through targeting of KRAS. In non-small-cell lung cancer, miR-613 is significantly decreased, and overexpression of miR-613 induces cell cycle arrest and inhibits cell growth through inhibition of CDK4 (34). Qiu et al (25) reported that miR-613 suppressed papillary thyroid cancer cell growth, migration and invasion via regulation of sphingosine kinase 2. A more recent study (24) reveals that miR-613 represses breast cancer cell proliferation and invasion by targeting vascular endothelial growth factor A. These studies indicated a tumor suppressive role of miR-613 that functions through inhibition of various oncogenes. Consistent with these studies, these findings supported the notion that miR-613 is a tumor suppressor that inhibits RCC cell proliferation and invasion by targeting FZD7, a well-known oncogene (18) . Interestingly, these findings are in line with a recent study demonstrating that miR-613 suppresses prostate cancer cell proliferation and invasion by targeting and inhibiting FZD7 (35) .
FZD7 is the Wnt receptor most commonly increased in numerous cancers that serves an important role in cancer development and progression (18) . Overexpression of FZD7 is also identified in RCC associated with RCC cell proliferation (23) . Therapies targeted at FZD7, including siRNA knockdown, neutralizing antibody and the extracellular peptide of FZD7, show considerable anti-tumor activity in vitro and in vivo (15, 19, 21, 36, 37) . In recent years, miRNAs have emerged as novel tools for gene expression. Therefore, targeting FZD7 by specific miRNAs may have the potential to treat cancers. To date, several miRNAs, including miR-27a (38) , miR-27b (39), miR-142-3p (40) and miR-199a (41), have been indicated to inhibit cancer progression through targeting of FZD7. In addition, other miRNAs, such as miR-1 and miR-184, also target and inhibit FZD7 in other pathological processes (42, 43) . These studies raise the possibility that targeting FZD7 by specific miRNAs is practicable. In the current study, the authors identified that miR-613 could also target and regulate FZD7 expression, as confirmed by dual-luciferase reporter assay, RT-qPCR and western blot analysis. The present findings are consistent with a recent study demonstrating that miR-613 targets and inhibits FZD7 (35) , further confirming the targeted relationship between miR-613 and FZD7.
In conclusion, the data presented by the present study suggested that miR-613 may serve as an anti-cancer therapeutic for RCC. Overexpression of miR-613 in RCC cell lines resulted in suppression of cell proliferation and invasion by inhibiting FZD7. The study may help to further elucidate the molecular mechanisms underlying RCC pathogenesis and provide candidate therapeutic targets for RCC.
